登革病毒重组亚单位疫苗的构建及免疫原性分析

目的 构建登革病毒1～4型重组亚单位疫苗,分析重组疫苗的免疫原性.方法 利用连接肽将登革病毒1型与2型,3型与4型的外膜蛋白DⅢ基因片段连接在一起,克隆人原核表达载体pET-30a,在大肠埃希菌中表达DEN1/2型、DEN3/4型融合重组蛋白.重组蛋白经高效液相色谱柱分离纯化后,混和免疫小鼠,采用中和实验法测定血清中和抗体效价,同时进行乳鼠体内中和实验,观察中和抗体对乳鼠的免疫保护作用.结果 重组蛋白能诱导小鼠产生针对登革病毒1～4型的中和抗体,平均中和效价分别为1：34.9、1：45.3、1：24.7和1：38.4.中和抗体能保护新生乳鼠免受致死剂量DEN1～4的攻击,保护率分别为100%,100%,83%,83%.结论 构建的重组亚单位疫苗具有良好的免疫原性,能诱导小鼠产生中和抗体,为构建单一四价疫苗提供了实验室依据.

Construction of sub-unit dengue vaccines and analysis of its immunogenicity

Objective To construct sub-unit vaccines of dengue virus type 1 to 4 and to analyze its immunogenicity. Methods Envelope domain Ⅲ s of dengue serotypes 1 and 2, as well as 3 and 4, were spliced by a linker (Gly-Gly-Ser-Gly-Ser) 3 and cloned into vector pET-30a, then transformed into E. coli to express recombinant fusion proteins. The recombinant proteins were purified by high-performance liquid chromatography and mixed to immunize BALB/c mice. The neutralizing antibodies were tested by neutralizing assay, as well as in newborn mice challenged intracranially with dengue virus type 1 to 4.combination with sera from mice immunized with recombinant proteins were protected, whereas 83% protection was obtained when challenged with DEN-3 or 4. Conclusion The recombinant proteins possess excellent immunogenicity to induce neutralizing antibodies and would be valuable for development of a tetravalent sub-unit vaccine.